# GH-Axis Peptide FAQ — Tesamorelin, Ipamorelin, MOTS-c — Get Peptides USA

> Frequently asked questions about three GH/IGF-1 axis research peptides — tesamorelin, ipamorelin and MOTS-c — answered from the peer-reviewed literature with citations.

Direct, citation-anchored answers to the questions readers most often bring to these three Growth Hormone Axis research peptides.

## What is tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone (GHRH), the signal the hypothalamus sends to tell the pituitary to release growth hormone. Its key structural feature is a lipophilic cap at one end that makes it more resistant to enzymatic breakdown than native GHRH, extending its duration of action [2]. It is FDA-approved to reduce excess abdominal fat in HIV-positive adults with antiretroviral-related lipodystrophy — that is its only approved use. All other uses are off-label and investigational [2]. It is not a growth hormone itself; it stimulates the pituitary to produce the body's own GH in natural pulses.

## What does tesamorelin do?

Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, triggering pulsatile secretion of endogenous growth hormone. That GH drives hepatic production of IGF-1, and together GH and IGF-1 promote lipolysis — fat breakdown — preferentially in visceral adipose tissue, the fat depot packed around the internal organs [1][3]. In its approved HIV population, multiple RCTs found it reduced visceral fat area by roughly 18–27 cm² versus placebo, decreased hepatic fat fraction, and modestly increased lean body mass [1][3]. Effects reverse on discontinuation — visceral fat reaccumulates within weeks of stopping [5].

## How does tesamorelin work?

It binds the pituitary GHRH receptor and activates a Gs → adenylyl cyclase → cAMP → PKA signaling cascade that stimulates GH synthesis and secretion [1][4]. Because it amplifies the body's own pulsatile GH rhythm rather than supplying constant exogenous GH, its metabolic and hormonal profile differs from recombinant GH: in healthy men, it raised overnight GH (+0.5 µg/L, P=0.004) and IGF-1 (+181 µg/L, P<0.0001) without significantly changing fasting glucose or insulin sensitivity [4]. The N-terminal trans-3-hexenoic acid modification on tesamorelin resists cleavage by dipeptidyl peptidase-IV (DPP-IV), which extends its action relative to native GHRH.

## Will tesamorelin help me lose belly fat?

In HIV-positive adults with antiretroviral-related lipodystrophy, tesamorelin produced statistically significant and clinically meaningful reductions in visceral fat in multiple RCTs, with a pooled effect of -27.71 cm² in a 2026 meta-analysis [1]. That is a real, replicated clinical signal. However: this approval and this evidence base apply specifically to HIV-associated lipodystrophy, not to general visceral fat reduction in people without that condition. Whether tesamorelin would produce comparable fat loss in a healthy, HIV-negative population has not been established by large controlled trials — that would be off-label use. This site provides no medical advice and lists no dosing information.

## What is ipamorelin?

Ipamorelin is a synthetic five-amino-acid peptide (sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells, triggering a discrete pulse of growth hormone release [11]. It is classified as a growth hormone secretagogue (GHS) — a compound that stimulates the body's own GH production rather than supplying exogenous GH. Its defining feature is selectivity: unlike earlier GHRPs (GHRP-6, GHRP-2), it does not significantly raise ACTH, cortisol, or prolactin, even at doses far above its GH threshold [11]. It has never been approved as a drug for any indication.

## What does ipamorelin do for you?

In preclinical models, ipamorelin triggers GH pulses from the pituitary, which downstream can elevate IGF-1 and promote lipolysis, lean-mass support, and bone growth [10][11]. In a rat model, it dose-dependently increased longitudinal bone growth rate without altering systemic IGF-1 levels, suggesting partly local skeletal effects [10]. In the only human clinical trial — adults undergoing bowel resection — it did not significantly shorten the time to first tolerated meal (the primary endpoint; P=0.15) [8]. Research-use community reports (anecdotal, not clinical evidence) cite deeper sleep, faster physical recovery, and gradually leaner body composition, along with transient flush, water retention, and injection-site reactions as common adverse effects.

## What is ipamorelin peptide?

Ipamorelin is a pentapeptide — a chain of five amino acids — in the growth hormone secretagogue class. It binds GHS-R1a, the same receptor that natural ghrelin (the "hunger hormone") activates, and uses a complementary and additive pathway to GHRH to stimulate GH release from the anterior pituitary [11]. It was characterized in 1998 and initially investigated for postoperative gastrointestinal conditions because GHS-R1a is expressed on enteric neurons governing motility [8]. Its only published Phase 2 human trial missed its primary endpoint [8]. In 2024, the FDA removed ipamorelin acetate from the interim 503A bulk-substances list that permitted its use by compounding pharmacies. It is marketed as a research chemical only.

## What are the risks of ipamorelin?

The evidence-based risks fall into several categories. First, the GH/IGF-1 axis mechanism itself carries class-level concerns: GH is a counter-regulatory hormone that reduces insulin sensitivity, and downstream IGF-1 elevation is theoretically concerning in proliferative or pre-malignant conditions [11]. Second, a 28-day study of a structurally related GHS-R1a agonist found dose-dependent myocardial degeneration in rats — a class-level cardiovascular signal [7]. Third, ipamorelin has a GH-independent insulinotropic action on pancreatic islet cells ex vivo, creating unpredictable metabolic interactions in subjects with glucose dysregulation [11]. Fourth, and most practically: the only controlled human safety dataset covers short intravenous administration in at most 114 surgical patients [8] and acute IV dosing in 8 volunteers [9]. Long-term subcutaneous use — the dominant real-world pattern — has no published human safety characterization at all.

## What does the MOTS-c peptide do?

MOTS-c is a 16-amino-acid mitochondrial-derived peptide that, in cell and animal studies, activates AMPK (a master metabolic switch) via disruption of the folate cycle and AICAR accumulation, improving glucose uptake and insulin sensitivity in skeletal muscle [15][17]. Under metabolic stress it translocates to the nucleus and regulates antioxidant and metabolic gene expression, including NRF2-dependent pathways [17]. A 2024 study identified casein kinase 2 (CK2) as its direct molecular target in muscle, and demonstrated it prevents skeletal muscle atrophy and enhances glucose uptake in mice via tissue-specific CK2 modulation [13]. In aged mice, exogenous MOTS-c improved running capacity, grip strength, and gait [16]. Human data are limited to observational biomarker associations in renal patients [14].

## What are the negative side effects of MOTS-c?

No community real-world signals for MOTS-c are compiled in this desk's source material, and no human interventional safety data exist. The cautions that follow come from the research literature and the regulatory record. MOTS-c has never been studied in a human clinical trial, so its adverse-effect profile in people is genuinely unknown [15]. Rodent doses used in preclinical studies (0.5–15 mg/kg/day) cannot be extrapolated to human use. Research-grade MOTS-c from unregulated suppliers carries variable purity and sterility without pharmaceutical quality assurance [15]. At least one mitochondrial DNA variant affecting MOTS-c function (m.1382A>C) has been linked to a pro-diabetogenic metabolic profile, suggesting population-level heterogeneity in response [15]. Anti-doping bodies treat MOTS-c as prohibited in competitive sport; athlete use risks sanctions [15].

## Is MOTS-c legal to buy?

In most jurisdictions, MOTS-c is available as a research chemical — meaning it can be purchased for laboratory research purposes from chemical suppliers. It is not an approved drug, dietary supplement, or prescription medicine anywhere, and it is not approved by the FDA for human use [15]. Its legal status for personal use or importation varies by country. In competitive sport, it is treated as prohibited by anti-doping authorities under hormone and metabolic-modulator categories [15]. If your question concerns use rather than research, you should consult a qualified legal or medical professional; this site provides no legal or medical advice.

## How often do you inject MOTS-c?

This desk does not provide dosing or administration guidance for any compound, including MOTS-c. There is no validated human pharmacokinetic data for MOTS-c — no measured half-life, bioavailability, or dose-response in people — so any injection frequency used in off-label research contexts is not grounded in established human PK science [15]. Rodent studies used a range of protocols, but animal doses cannot be directly translated to human use. MOTS-c has not completed any human clinical trial [14][15]. This question belongs to a qualified medical provider operating in a clinical research context, not to an editorial literature digest.

---

A reference desk, not a clinic: this site reads the GH-axis literature so you can see what the evidence actually says.